Myocardial injury and COVID-19: Serum hs-cTnI level in risk stratification and the prediction of 30-day fatality in COVID-19 patients with no prior cardiovascular disease.

MLA

Cao, Jiatian, et al. “Myocardial Injury and COVID-19: Serum Hs-CTnI Level in Risk Stratification and the Prediction of 30-Day Fatality in COVID-19 Patients with No Prior Cardiovascular Disease.” Theranostics, vol. 10, no. 21, July 2020, pp. 9663–73. EBSCOhost, https://doi.org/10.7150/thno.47980.

APA

Cao, J., Zheng, Y., Luo, Z., Mei, Z., Yao, Y., Liu, Z., Liang, C., Yang, H., Song, Y., Yu, K., Gao, Y., Zhu, C., Huang, Z., Qian, J., & Ge, J. (2020). Myocardial injury and COVID-19: Serum hs-cTnI level in risk stratification and the prediction of 30-day fatality in COVID-19 patients with no prior cardiovascular disease. Theranostics, 10(21), 9663–9673. https://doi.org/10.7150/thno.47980

Chicago

Cao, Jiatian, Yan Zheng, Zhe Luo, Zhendong Mei, Yumeng Yao, Zilong Liu, Chao Liang, et al. 2020. “Myocardial Injury and COVID-19: Serum Hs-CTnI Level in Risk Stratification and the Prediction of 30-Day Fatality in COVID-19 Patients with No Prior Cardiovascular Disease.” Theranostics 10 (21): 9663–73. doi:10.7150/thno.47980.